Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5078-5084

  Monno, Laura ^a   Annalisa, Saracino ^b   Scudeller, Luigia ^c   Punzi, Grazia ^a   Brindicci, Gaetano ^a   Altamura, Maurantonio ^a   Lagioia, Antonella ^a   Ladisa, Nicoletta ^a   Angarano, Gioacchino ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN GP 120;

ADULT; AGED; AIDS PATIENT; AMINO ACID SUBSTITUTION; ARTICLE; CODON; DISEASE COURSE; ELECTROPHORESIS; ENHANCED SENSITIVITY TROFILE ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRAL TROPISM; VIRUS MUTATION; VIRUS STRAIN;

ADULT; AGED; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRAL TROPISM; YOUNG ADULT;

EID: 80054690690     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00743-11     Document Type: Article

References (38)

1. Björndal, Å., et al. 1997. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71:7478-7487. (Pubitemid 27391688)
2. Boyd, M. T., G. R. Simpson, A. J. Cann, M. A. Johnson, and R. A. Weiss. 1993. A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism. J. Virol. 67:3649-3652. (Pubitemid 23143749)
3. Cardozo, T., et al. 2007. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res. Hum. Retrovir. 23:415-426. (Pubitemid 46608562)
4. Carrillo, A., and L. L. Ratner. 1996. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J. Virol. 70:1301-1309. (Pubitemid 26029061)
5. Cho, M. W., et al. 1998. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J. Virol. 72:2509-2515. (Pubitemid 28100815)
6. Cooper, D. A., et al. 2010. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 201:803-813.
7. Fouchier, R. A., M. Brouwer, S. M. Broersen, and H. Schuitemaker. 1995. Simple determination of human immunodeficiency virus type 1 syncytiuminducing V3 genotype by PCR. J. Clin. Microbiol. 33:906-911.
8. Fouchier, R. A. M., et al. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gpl20 molecule. J. Virol. 66:3183-3187.
9. Goodenow, M. M., and R. G. Collman. 2006. HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J. Leukoc. Biol. 80:965-972. (Pubitemid 44646302)
10. Groenink, M., et al. 1992. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J. Virol. 66:6175-6180.
11. Gulick, R. M., et al. 2008. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 359:1429-1441.
12. Hoffman, N. G., F. Seillier-Moiseiwitsch, J. Ahnn, J. M. Walker, and R. Swanstrom. 2002. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J. Virol. 76:3852-3864. (Pubitemid 34250550)
13. Irlbeck, D. M., H. Amrine-Madsen, K. M. Kitrinos, C. C. LaBrance, and J. F. Demarest. 2008. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS 22:1425-1431.
14. Jansson, M., et al. 2001. Length variation of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res. Hum. Retrovir. 17:1405-1414. (Pubitemid 33042808)
15. Jensen, M. A., et al. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV-1 env V3 loop sequences. J. Virol. 77:13376-13388. (Pubitemid 37494331)
16. McGovern, R. A., et al. 2010. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24:2517-2525.
17. Mild, M., et al. 2010. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. Infect. Genet. Evol. 10:356-364.
18. Monno, L., et al. 2010. V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients. AIDS Res. Hum. Retrovir. 26:365-372.
19. Mosier, D. E. 2009. How HIV changes its tropism: evolution and adaptation? Curr. Opin. HIV AIDS 4:125-130.
20. Moyle, G. J., et al. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191:866-872. (Pubitemid 40349800)
21. Pollakis, G., et al. 2001. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276:13433-13441.
22. Raymond, S., et al. 2010. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 24:2305-2312.
23. Recordon-Pinson, P., et al. 2010. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob. Agents Chemother. 54:3335-3340.
24. Reeves, J. D., E. Coakley, C. J. Petropoulos, and J. M. Whitcomb. 2009. An enhanced-sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J. Viral Entry 3:94-102.
25. Repits, J., et al. 2008. Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology 379:125-134.
26. Repits, J., et al. 2005. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J. Gen. Virol. 86:2859-2869. (Pubitemid 41410478)
27. Resch, W., N. Hoffman, and R. Swanstrom. 2001. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 288:51-62. (Pubitemid 32846473)
28. Saag, M., et al. 2009. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J. Infect. Dis. 199:1638-1647.
29. Saracino, A., et al. 2010. Are the proposed env mutations actually associated with resistance to maraviroc? J. Acquir. Immune Defic. Syndr. 53:550-552.
30. Saracino, A., et al. 2007. HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples. Virus Res. 130:34-42. (Pubitemid 350051085)
31. Seclén, E., et al. 2010. Impact of baseline HIV-1 tropism on viral response and CD4 gains in antiretroviral-naïve patients. J. Int. AIDS Soc. 13(Suppl. 4):O10.
32. Sing, T., et al. 2007. Predicting HIV coreceptor usage based on genetic and clinical covariates. Antivir. Ther. 12:1097-1106. (Pubitemid 350114990)
33. Sterjovski, J., et al. 2007. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology 4:89.
34. Svicher, V., et al. 2011. Signature mutations in V3 and bridging sheet domain of HIV-1 gp120 HIV-1 are specifically associated with dual tropism and modulate the interaction with CCR5 N-terminus, abstr. 591. Abstr. 18th Conf. Retrovir. Opportun. Infect., Boston, MA, 27 February to 2 March 2011.
35. Thielen, A., et al. 2010. Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120. J. Infect. Dis. 202:1435-1443.
36. Toma, J., J. M. Whitcomb, C. J. Petropoulos, and W. Huang. 2010. Dualtropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors. AIDS 24:2181-2186.
37. Vandekerckhove, L., et al. 2011. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect. Dis. 11:394-407.
38. Wilkin, T. J., et al. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS clinical trial group A5211. Clin. Infect. Dis. 44:591-595. (Pubitemid 46233265)